November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

Glucagon-like peptide 1 receptor agonists and fenofibrates may protect patients with type 2 diabetes against diabetic macular ...

Struggles with obesity are a longstanding issue for millions of Americans and thousands of Iowans, but recent advancements in ...

Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart ...

A panelist discusses how glucagon-like peptide-1 receptor (GLP-1) agonists' cardioprotective effects likely stem from multiple physiological mechanisms, including reduced inflammation, improved ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...